IP Library Granted Patent US 8,742,089
Granted Patent B2
US 8,742,089 · App. 13/601,401 · Granted Jun 3, 2014

Methods and compositions for expressing negative-sense viral RNA in canine cells

Inventors: Gregory Duke (Redwood City, CA); George Kemble (Saratoga, CA); James Young (Potomac, MD); Zhaoti Wang (Palo Alto, CA)
Assignee: MedImmune, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,742,089
App. No.
13/601,401
Granted
Jun 3, 2014
Kind
B2
Abstract

The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.

Claims (25)

1. A vector comprising:

(a) canine DNA, which canine DNA consists of a subsequence of genomic canine DNA comprising (i) the polynucleotide of SEQ ID NO:1, (ii) a polynucleotide having at least 98% identity to the polynucleotide of SEQ ID NO:1, or (iii) a fragment of the polynucleotide defined in (i) or (ii) comprising at least nucleotides 1559 to 1808 of SEQ ID NO:1; or

(b) the complement or reverse complement of (a).

2. The vector of claim 1 , which comprises the fragment in (a)(iii), wherein the fragment comprises nucleotides 1340 to 1808 of SEQ ID NO:1.

3. The vector of claim 1 , which comprises the fragment in (a)(iii), wherein the fragment comprises nucleotides 1 to 1808 of SEQ ID NO:1.

4. An isolated cell comprising the vector of claim 1 .

5. An isolated nucleic acid comprising:

(a) canine DNA, which canine DNA consists of a subsequence of genomic canine DNA comprising (i) the polynucleotide of SEQ ID NO:1, (ii) a polynucleotide having at least 98% identity to the polynucleotide of SEQ ID NO:1, or (iii) a fragment of the polynucleotide defined in (i) or (ii) comprising at least nucleotides 1559 to 1808 of SEQ ID NO:1, or

(b) the complement or reverse complement of (a); and

(c) a heterologous polynucleotide.

6. The isolated nucleic acid of claim 5 , which comprises the fragment in (a)(iii), wherein the fragment comprises nucleotides 1340 to 1808 of SEQ ID NO:1.

7. The isolated nucleic acid of claim 5 , which comprises the fragment in (a)(iii), wherein the fragment comprises nucleotides 1 to 1808 of SEQ ID NO:1.

8. The isolated nucleic acid of claim 5 , wherein the heterologous polynucleotide comprises one or more influenza virus genome segments.

9. The isolated nucleic acid of claim 5 , wherein the polynucleotide of (a) or (b) and the polynucleotide of (c) are operably linked.

10. The isolated nucleic acid of claim 6 , wherein the polynucleotide of (a) or (b) and the polynucleotide of (c) are operably linked.

11. The isolated nucleic acid of claim 7 , wherein the polynucleotide of (a) or (b) and the polynucleotide of (c) are operably linked.

12. The isolated nucleic acid of claim 8 , wherein the polynucleotide of (a) or (b) and the polynucleotide of (c) are operably linked.

13. The isolated nucleic acid of claim 5 , which is a vector.

14. An isolated cell comprising the isolated nucleic acid of claim 13 .

15. The isolated nucleic acid of claim 8 , which is a vector.

16. An isolated cell comprising the isolated nucleic acid of claim 15 .

17. The isolated nucleic acid of claim 9 , which is a vector.

18. An isolated cell comprising the isolated nucleic acid of claim 17 .

19. The isolated nucleic acid of claim 12 , which is a vector.

20. An isolated cell comprising the isolated nucleic acid of claim 19 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2014
From: DUKE, GREGORY; KEMBLE, GEORGE; YOUNG, JAMES; WANG, ZHAOTI
To: MEDIMMUNE VACCINES, INC
Reel/Frame 032865/0547 →
CHANGE OF NAME Recorded May 10, 2014
From: MEDIMMUNE, INC
To: MEDIMMUNE, LLC
Reel/Frame 032865/0569 →
CHANGE OF NAME Recorded May 10, 2014
From: MEDIMMUNE VACCINES, INC
To: MEDIMMUNE, INC
Reel/Frame 032865/0776 →
Continuity (11)
Continuation 12842854 · Jul 23, 2010
Division 11501067 · Aug 9, 2006
Continuation In Part 11455734 · Jun 20, 2006
Provisional Application 60793522 · Apr 19, 2006
Provisional Application 60793525 · Apr 19, 2006
Provisional Application 60702006 · Jul 22, 2005
Provisional Application 60699556 · Jul 15, 2005
Provisional Application 60699555 · Jul 15, 2005
Provisional Application 60692965 · Jun 21, 2005
Provisional Application 60692978 · Jun 21, 2005
Related Publication 20120329150A1 · Dec 27, 2012